The two drugmakers will co-develop Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody drug in clinical trials for breast cancer and other solid tumors.
They will also test the drug in combination with Merck’s cancer immunotherapy Keytruda.
Under the deal, Seattle Genetics is eligible for progress-dependent payments of up to $2.6 billion from Merck.
Seattle Genetics also granted Merck an exclusive license to commercialize Tuksya, its drug designed to treat HER2-positive cancers. Under that deal, Seattle Genetics will receive $125 million from Merck and is eligible for progress-dependent payments of up to $65 million.
Read the full news release here.
More articles on pharmacy:
Trump signs new exec order aimed at lowering drug prices
Baptist Health opens 2 new retail pharmacies
AstraZeneca resumes UK vaccine trial after halting due to participant’s adverse reaction
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
